Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s first product, lomitapide, received marketing approval, under the brand name Juxtapid capsules, from the United States Food and Drug Administration as an adjunct to a low-fat diet and other lipid-lowering treatments in adult patients with homozygous familial hypercholesterolemia (HoFH). The Company launched Juxtapid in the United States in January 2013 and received marketing authorization for lomitapide in the European Union, under the brand name Lojuxta hard capsules in July, 2013. Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. It sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the United States and the European Union where such sales are authorized based on the regulatory approval.